HØRSHOLM, Denmark--(BUSINESS WIRE)--ALK's partner MSD, known as Merck (NYSE: MRK) in the US and Canada, publishes positive results from an environmental exposure chamber trial evaluating the efficacy of the dust mite allergy tablet.